BioCentury
ARTICLE | Clinical News

CuraGen dropping velafermin

October 12, 2007 1:10 AM UTC

CRGN discontinued development of velafermin after the human fibroblast growth factor 20 ( FGF-20) failed to significantly decrease the incidence of severe mucositis vs. placebo, the primary endpoint, in a Phase II trial to prevent oral mucositis (OM). The double-blind, U.S. study enrolled 390 bone marrow transplant patients receiving high-dose chemotherapy. ...